KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Change in Cash (2016 - 2025)

Edwards Lifesciences has reported Change in Cash over the past 17 years, most recently at $244.7 million for Q4 2025.

  • Quarterly results put Change in Cash at $244.7 million for Q4 2025, up 139.18% from a year ago — trailing twelve months through Dec 2025 was -$119.3 million (down 106.24% YoY), and the annual figure for FY2025 was -$119.3 million, down 106.24%.
  • Change in Cash for Q4 2025 was $244.7 million at Edwards Lifesciences, up from -$595.2 million in the prior quarter.
  • Over the last five years, Change in Cash for EW hit a ceiling of $2.0 billion in Q3 2024 and a floor of -$652.5 million in Q4 2021.
  • Median Change in Cash over the past 5 years was $119.4 million (2021), compared with a mean of $87.0 million.
  • Biggest five-year swings in Change in Cash: tumbled 482.25% in 2021 and later skyrocketed 1905.38% in 2022.
  • Edwards Lifesciences' Change in Cash stood at -$652.5 million in 2021, then increased by 26.57% to -$479.1 million in 2022, then skyrocketed by 44.5% to -$265.9 million in 2023, then crashed by 134.9% to -$624.6 million in 2024, then skyrocketed by 139.18% to $244.7 million in 2025.
  • The last three reported values for Change in Cash were $244.7 million (Q4 2025), -$595.2 million (Q3 2025), and $141.2 million (Q2 2025) per Business Quant data.